Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinoma
Antineoplastic Combined Chemotherapy Protocols
Hearing Loss, Sensorineural
There was a significant increase in risk of SNHL among patients receiving > 48 Gy, suggesting a threshold in cochlear radiation dose-response in the setting of combined modality therapy. This dose should serve as a Dmean constraint maximum for intensity-modulated radiotherapy treatment of nasopharynx carcinoma.